As our clinical trials progress with increasing global footprint, our clinical-stage products have also received continuous recognition from our partners as we are granted with impressive payment or are entitled to co-developed late-stage products with Nasdaq-listed partners. The globalized efforts of clinical research and business development will also prepare GenFleet for a globalized strategy of commercialization in advance.
Staff with Master or Doctoral Degrees
GenFleet sets up a cutting-edge pipeline of innovative therapies with a view to our prospective and highly differentiated strategy: we basically choose biological targets or pathways that have not achieved proof of concept in clinical trials across the globe. Our proprietary and fully integrated R&D platform and diversified co-development programs promote the company's continuous innovative drug discovery and clinical progress.
As our clinical trials progress with increasing global footprint, our clinical-stage products have also received continuous recognition from our partners home and abroad. The globalized efforts of clinical research and business development will also prepare GenFleet for a globalized strategy of commercialization in advance.
At present, two phase II studies are actively underway in China and the US, focusing on the treatment of PTCL and AML respectively. A number of subjects in these GFH009 studies have shown partial or complete responses, which underscores the superior safety profile and efficacy of GFH009 in the global arena of CDK9 inhibitor development.
The abstract with results from GFH925 monotherapy treating NSCLC in the registrational phase II study (NCT05005234) was accepted as a LBA (Late-breaking abstracts) program in 2023 ESMO Asia, after the New Drug Application for GFH925 monotherapy treating NSCLC patients was recently accepted by National Medical Products Administration and granted with Priority Review Designation. The data demonstrated encouraging antitumor activity and favorable tolerability of GFH925 among NSCLC patients, with a
It’s the first China-developed KRAS G12C inhibitor that has its NDA submission accepted and granted with Priority Review Designation by NMPA. GFH925 also received Breakthrough Therapy Designations this year for treating advanced KRAS G12C-mutant NSCLC that have received at least one systemic therapy and colorectal carcinoma (CRC) patients who have received at least two systemic therapies.